Akebia Therapeutics (AKBA) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The Phase 2 study titled “A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Praliciguat in Patients With Biopsy-Confirmed Focal Segmental Glomerulosclerosis” aims to test Akebia Therapeutics’ drug praliciguat in adults with focal segmental glomerulosclerosis. The goal is to see if the treatment can safely reduce kidney damage in a hard-to-treat disease where options are limited.
Praliciguat is an oral tablet designed to improve blood flow in small vessels and protect organs, in this case the kidneys. The study compares daily praliciguat to a matching placebo to see if treated patients show better kidney outcomes over time.
The trial is interventional and randomized, meaning participants are assigned by chance to praliciguat or placebo in parallel groups. It uses triple masking so patients, doctors, and outcome assessors do not know who gets the drug, and the main goal is to test whether praliciguat works as a treatment rather than just observing patients.
The study is currently recruiting and started after its first submission on November 26, 2025, marking the point when the trial entered the regulatory system. The most recent update on February 9, 2026 signals that the protocol and status have been refreshed, which matters for investors tracking operational progress and timelines toward future data readouts.
For Akebia (AKBA), this update reinforces its effort to expand beyond anemia into kidney diseases like FSGS, an area with high unmet need and potential premium pricing. Positive Phase 2 data could support a differentiated renal pipeline story versus larger kidney players and rare disease peers, improving sentiment and giving the stock optionality ahead of late-stage partnering or development decisions.
At the same time, investors should note that this is still mid-stage and carries typical clinical risk, while competitors pursue other kidney pathways and established players defend their nephrology franchises. The ongoing status and fresh update on ClinicalTrials.gov suggest the program is active and progressing, with more detailed information available on the ClinicalTrials portal.
To learn more about AKBA’s potential, visit the Akebia Therapeutics drug pipeline page.